CIK 0001831828 · Large accelerated filer
Vera Therapeutics, Inc.
Sign in to watch- Ticker
- VERA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812744449
- Phone
- 650-770-0077
- Business address
- 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE, CA, 94005
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,334,142
- in 2 filings, $1.3M under 10b5-1 plans
Net −$1,334,142. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 98 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-04 | Grant Sean CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2026-02-04 | Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR | Grant or award | +10,000 | 67,839 | ||
| 2026-02-04 | Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-02-04 | Fordyce Marshall PRESIDENT AND CEO | Grant or award | +68,800 | 274,088 | ||
| 2026-02-04 | Fordyce Marshall PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +137,500 | 137,500 | ||
| 2026-02-04 | Turner William D. Chief Regulatory Officer | Grant or award | +25,000 | 47,500 | ||
| 2026-02-04 | Turner William D. Chief Regulatory Officer | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2026-02-04 | JOHNSON DAVID LEE Chief Operating Officer | Grant or award | +20,000 | 48,306 | ||
| 2026-02-04 | JOHNSON DAVID LEE Chief Operating Officer | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2025-12-15 | Turner William D. Chief Regulatory Officer | Option exercise 10b5-1 | +10,000 | $15.53 | $155K | 32,500 |
| 2025-12-15 | Turner William D. Chief Regulatory Officer | Sale 10b5-1 | −10,000 | $50.08 | $501K | 22,500 |
| 2025-12-15 | Turner William D. Chief Regulatory Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | 245,000 | ||
| 2025-12-11 | ENRIGHT PATRICK G Director | Purchase | +5,882 | $42.50 | $250K | 5,882 |
| 2025-12-08 | Turner William D. Chief Regulatory Officer | Option exercise 10b5-1 | +10,000 | $15.53 | $155K | 32,500 |
| 2025-12-08 | Turner William D. Chief Regulatory Officer | Sale 10b5-1 | −10,000 | $45.31 | $453K | 22,500 |
| 2025-12-08 | Turner William D. Chief Regulatory Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | 255,000 | ||
| 2025-12-03 | Turner William D. Chief Regulatory Officer | Option exercise 10b5-1 | +10,000 | $15.53 | $155K | 32,500 |
| 2025-12-03 | Turner William D. Chief Regulatory Officer | Sale 10b5-1 | −10,000 | $40.00 | $400K | 22,500 |
| 2025-12-03 | Turner William D. Chief Regulatory Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | 265,000 | ||
| 2025-11-25 | Meyers James R Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 |
Page 4 of 17 · 321 trades